A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer

By sjmartinez • March 25, 2024

Cristea MC, Stewart D, Synold T, Ruel N, Mortimer J, Wang E, Jung A, Wilczynski S, Konecny GE, Eng M, Kilpatrick L, Han E, Dellinger T, Hakim A, Lee S, Morgan RJ, Wakabayashi MT, Frankel PH. A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer. Gynecol Oncol. 2024 Mar;182:124-131. doi: 10.1016/j.ygyno.2023.12.017. Epub 2024 Jan 22. PMID: 38262235.

Tags: Endometrial cancer, Epithelial ovarian cancer, Folate receptor alpha, FRα, gemcitabine, Hematology/Oncology, MIRV, Mirvetuximab soravtansine, Platinum-resistance, Publications, Triple negative breast cancer

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus

Alban J, Bowen RC, Reichstein DA, McKean M, Lutzky J, Weis E, Carvajal RD, Dulka S, Morse BG, Butler MO, Rapisuwon S, Kim KB, Chandrasekaran[...]

The Next Chapter of Cancer Immunology Research

Jaffee EM, Ribas A. The Next Chapter of Cancer Immunology Research. Cancer Immunol Res. 2026 Jan 8;14(1):8-9. doi: 10.1158/2326-6066.CIR-25-1391. PMID: 41502310.

Transarterial Radioembolization (TARE) Complicated by a Mycotic Aneurysm and Bleeding: A Case Presentation and Literature Review

Hu EH. Transarterial Radioembolization (TARE) Complicated by a Mycotic Aneurysm and Bleeding: A Case Presentation and Literature Review. Cureus. 2025 Dec 4;17(12):e98484. doi: 10.7759/cureus.98484. PMID:[...]